Dried Blood Spot Collection Cards Market By Product Type (Whatman 903 Cards, FTA Cards, Others), By Application (Infectious Disease Testing, Newborn Screening, Metabolic Disorder Testing, Toxicology Studies, Genomic & Proteomic Research), By End-user (Hospitals & Diagnostic Labs, Research Laboratories, Pharmaceutical & Biotechnology Companies, Forensic Laboratories), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Dried Blood Spot Collection Cards market accounted for USD 403.8 Million in 2024 and is expected to reach USD 676.3 Million by 2035, growing at a CAGR of around 4.8% between 2025 and 2035. The Dried Blood Spot (DBS) Collection Cards Market consists of producing and implementing purpose-made cards that enable blood specimen collection and long-term storage as dried blood matter.

The DBS technology is a minimally invasive, cost-effective, stable blood sampling method that is well-suited to work in remote areas and large screening projects. These collection cards find extensive use in different healthcare applications, including newborn screening programs, infectious disease monitoring and treatment drug monitoring, and biomarker assessment. Market growth appears because of developments in automation systems as well as bioanalytical methods and expanded healthcare accessibility. The adoption of DBS technology for disease screening receives support from government bodies along with healthcare institutions, particularly in locations where resources remain limited.

Report Scope:

Market Dynamics

Rising demand for minimally invasive blood sampling methods in clinical diagnostics globally

The Dried Blood Spot Collection Cards Market is expanding because clinical diagnostics require increasing numbers of minimally invasive blood sampling methods. The traditional venipuncture techniques often cause discomfort to patients because dried blood spot collection provides a convenient no-pain solution through finger blood draws. The testing method can acquire tiny blood samples through finger pricks, which makes it suitable for newborn tests, therapeutic drug checks, and analysis of infectious diseases.

Modern DBS technology advancements enable stable bloodspot samples that can stay viable at room temperature, prolonging their storage and transport capabilities. The technology proves most useful in distant healthcare environments and field-based trials since it simplifies difficult blood-drawing procedures. The DBS technology benefits proteomic and genomic research because researchers use its efficiency to discover biomarkers, while its expanding market application demonstrates the power of this method. The market's total expansion is supported by increasing demand for DBS-based testing, owing to healthcare providers' need for efficient diagnostic solutions that people can accept easily.

Expanding newborn screening programs boosting the adoption of dried blood spot technology

The Dried Blood Spot (DBS) Collection Cards Market demonstrates rapid growth because the increasing focus on newborn screening programs leads medical facilities to implement DBS technology. Newborn screening relies on reliable sampling methods to discover metabolic diseases, together with genetic and infectious diseases, at an early stage. Healthcare professionals utilize DBS technology because it is cost-effective, along with minimally invasive service combined with stable blood spot maintenance. The expanding government support for newborn screening plus health policies leads to increased demand for DBS collection cards. 

Newborn screening program growth has expedited the Dried Blood Spot Collection Cards Market by providing universal access to early diagnostic tools. DBS creates convenient conditions for sample handling and storage, thus making it appropriate for resource-limited and remote areas. An improvement in standards of neonatal healthcare will drive DBS technology adoption, which will ensure prompt diagnosis along with treatment for congenital conditions.

Limited sample volume restricting extensive biomarker analysis compared to traditional blood sampling

The Dried Blood Spot Collection Cards Market encounters substantial restrictions because the limited amount of blood samples prevents complete biomarker analysis. Traditional blood sampling produces larger blood samples to support high-sensitive testing for multiple examinations. The volume of blood drawn from DBS cards remains restricted thus, scientists are restricted in their ability to detect various biomarkers accurately. Sufficient biochemical profiling requires large sample exposure, which creates a major obstacle for diagnostic applications and screening metabolites in patients with complex medical conditions. 

A main drawback of the Dried Blood Spot Collection Cards Market exists in its limited ability to detect low-abundance biomarkers sufficiently. A low sample volume for testing creates detection problems because target analytes reach insufficient amounts for reliable measurement. The test reliability may be affected by inconsistent blood spot distribution mechanisms that contribute to sample variability. The restricted use of DBS in quantitative investigations and precise analysis works against its widespread clinical and research implementation.

Advancements in automation and analytical techniques enhancing dried blood spot applications globally

The Dried Blood Spot Collection Cards Market obtains advantages from novel automation methods and analytical techniques that increase DBS technology applications in worldwide markets. Automation of sample processing systems promotes higher laboratory efficiency and increases sample volume while reducing human processing mistakes. DBS technology has become more practical for major applications such as clinical diagnosis, pharmacy studies, and disease surveillance through recent innovative advancements. Process automation has made DBS stand out as a better method for biomarker testing and disease screening, which has led to its growing popularity. 

The Dried Blood Spot Collection Cards Market is experiencing growth because advanced analytical techniques improve both the sensitivity and detection accuracy of biomarkers. Dried blood spot analysis continues to advance through new applications that include individualized medicine as well as therapeutic drug supervision and disease-tracking systems. Ongoing technological developments have made DBS a progressively significant medical research and global healthcare instrument.

 Expanding use in infectious disease surveillance and therapeutic drug monitoring market

The Dried Blood Spot Collection Cards Market shows increased acceptance because it gained traction from its use in both infectious disease surveillance programs and therapeutic drug monitoring operations. The clinical implementation of DBS technology supports cost-effective disease screening operations that require minimal invasiveness, especially for people living in remote areas with limited resources. The technology provides trustworthy disease diagnosis capabilities for HIV, hepatitis, and malaria through biomarker protection beyond standard refrigeration requirements. DBS technology proved itself as an essential component for worldwide health programming along with epidemiological research and investigations. 

The expanded need for tailored medical practices and exact drug dosage requirements drives the Dried Blood Spot Collection Cards Market toward therapeutic drug monitoring (TDM). DBS acts as an efficient system to collect test samples easily, which determines drug concentrations for people receiving long-term care because of epilepsy or cardiovascular issues and organ transplant recipients. The Dried Blood Spot Collection Cards Market grows due to better bioanalytical techniques that enhance both the sensitivity and accuracy of drug measurements from DBS samples. Healthcare organizations place patient-focused monitoring at the center of their initiatives, which results in DBS measuring success in therapeutic drug monitoring (TDM) and infectious disease surveillance applications.

Industry Experts Opinion

“Dried blood samples offer many advantages for clinical trials and remote applications, but collection methods have long been a burden on patients, relying on painful finger sticks and messy blood spotting to obtain samples. Our next-generation dried blood collection systems enable a better patient experience alongside new process improvements.”

•  Ben Casavant, PhD, CEO and Co-Founder of Tasso.

“The new sampling card automates the entire collection process, making it the ultimate at-home sampling product for dried plasma-like material. The cells are separated from the blood at the site of collection without centrifugation and with minimal user requirements, making the microfluidic technology we have developed unique and outstanding in the microsampling segment.”

• Anna Ohlander, R&D Manager at Capitainer

Segment Analysis

Based on Product Type, the Dried Blood Spot Collection Cards Market is classified as Whatman 903 Cards, FTA Cards, and Others. Whatman 903 Cards control the market due to their proven reliability for newborn screening combined with excellent sample preservation properties. The popularity of FTA Cards continues to grow because these products establish extended DNA preservation capabilities and shield genomic material from environmental damage. The market expands because of the rising clinical diagnostics and research sectors' need for premium-quality collection tools. The market’s leadership role stays with Cytiva and PerkinElmer because these companies persist in developing better DBS card processes. Modern developments in filter paper engineering enhance both absorption capabilities for samples and their storage solutions. The segment expands because healthcare providers increasingly use DBS as part of decentralized testing procedures. 

Based on Application, the Dried Blood Spot Collection Cards Market is classified as infectious disease testing, newborn screening, metabolic disorder testing, toxicology studies, and genomic & proteomic research. The largest segment in newborn screening emerges from government regulations together with the rising detection of early diseases. The field of infectious disease testing is expanding quickly because it requires cost-efficient and distant sample collection solutions, mostly for environments with limited resources. The adoption of DBS technology for genomic and proteomic research improves the identification of biomarkers, which supports personal medicine development. Toxicology research demonstrates advantages through DBS technology, which provides storage capability for maintaining drug and substance samples in persistent states. Progress in mass spectrometry combined with molecular diagnostic techniques improves the detection of diseases by DBS technology and its research capabilities.

Regional Analysis

The North American region leads the Dried Blood Spot (DBS) Collection Cards Market due to its established healthcare infrastructure, which matches up with extensive newborn screening program usage. The market expands because major companies such as QIAGEN, PerkinElmer, and Thermo Fisher Scientific continuously innovate DBS technology. Scientists have recently achieved two significant innovations through automated DBS sample automation and digital integrated health platforms that offer immediate data evaluation. The area observes improved usage between therapeutic drug monitoring services and forensic examination activities. The market receives additional demand through government programs aiming to detect diseases at early stages. Research institutions that work together with diagnostic companies manage to develop precise, high-precision DBS-based testing solutions. 

The Asia-Pacific territory holds the status of the fastest-growing region in the Dried Blood Spot Collection Cards Market through its expanding healthcare visibility along with increased newborn screening activities throughout China, India, and Japan. Market expansion occurs because consumers want decentralized diagnostic solutions and personalized medical care. Businesses worldwide introduce low-cost DBS systems that suit emerging markets to achieve better market penetration. The development of mobile-compatible DBS collection kits now enables remote patient monitoring of diseases combined with surveillance functions. Market expansion benefits from public investments that expand diagnostic facilities. The accuracy and reliability of DBS-based testing in the region get better due to biomarker analysis and mass spectrometry developments.

Competitive Landscape

The competitive Dried Blood Spot (DBS) Collection Cards Market has key players who direct their efforts toward developing innovations alongside forming strategic partnerships while seeking market expansion. QIAGEN N.V. and PerkinElmer Inc. maintain their position in front of the market through their advanced solutions for DBS collection and processing, which improve diagnostic outcomes. F. Hoffmann-La Roche AG increases its clinical diagnostic strength through high-throughput analysis automation technology investments. Ahlstrom-Munksjö, along with Pall Corporation, dedicates its efforts to producing superior filter papers that enhance both sample stability and experimental reliability. 

The genetic testing solutions alongside personalized medicine development from Eastern Business Forms Inc. together with Centogene N.V. lead to better rare disease diagnostic adoption. Thermo Fisher Scientific Inc. teamed up with Danaher Corporation to link pupillary dried blood spot collection with mass spectrometry-based biomarker assessment systems, which strengthened their therapeutic drug monitoring solutions. The companies DBS System SA and ARCHIMED Life Science GmbH are developing micro-sampling technologies that assist decentralized clinical trials.

Dried Blood Spot Collection Cards Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In February 2025, Researchers from Tufts University developed a paper-based blood collection card that can be used for HIV viral load testing to improve accuracy compared to standard-of-care devices.
• In February 2025, Tasso, Inc., the leading provider of patient-centric, clinical-grade blood collection solutions, announced the launch of its next-generation technology for dried blood spot (DBS) sample collection. The novel collection system combines Tasso’s new Tile™-T20 dried whole blood cartridge with a Tasso™ Mini device, enabling the precise, convenient collection of DBS samples for clinical trials and sports anti-doping testing.

Report Coverage:

By Product Type

• Whatman 903 Cards
• FTA Cards
• Others

By Application

• Infectious Disease Testing
• Newborn Screening
• Metabolic Disorder Testing
• Toxicology Studies
• Genomic & Proteomic Research

By End-user

• Hospitals & Diagnostic Labs
• Research Laboratories
• Pharmaceutical & Biotechnology Companies
• Forensic Laboratories

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• QIAGEN
• PerkinElmer
• F. Hoffmann-La Roche Ltd
• ARCHIMEDLife GmbH
• Centogene N.V.
• Eastern Business Forms. Inc
• Ahlstrom
• Shimadzu Corporation
• Pall Corporation
• Hemaxis
• Danaher Corporation
• Novilytic
• Rhinostics
• GE HealthCare
• Thermo Fisher Scientific Inc.

Frequently Asked Questions (FAQs)